The report content will help all global companies to better understand the opportunities presented by recent developments in Europe orphan drug legislation. Over the last 4 years the legislation has provided opportunities for large and small companies employing deliberate or add-on orphan drug development programmes. As has been shown through the success of the more mature market environment for US orphan medicines, the impact of European measures is likely to be significant and is only just beginning to materialise.

The report uses detailed regulatory, company and primary source information in order to provide a detailed guide to employing orphan drug development and marketing strategies in Europe. The report looks first at the global opportunity for orphan medicines, before outlining the European regulations and procedures in full detail. In order to assess the impact of the legislation, both designated and subsequently launched orphan drugs are analysed and profiled. Detailed case studies lead to a set of key conclusions and recommendations for all pharmaceutical and biotechnology companies.

Related Reports:
Snapshots US Pharmaceuticals 2009
Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis
Pharmaceuticals Industry Report
BI for Drug Development: Oracle Introduces Clinical Development Analytics
Pharmaceutical Industry in Mexico
Asia Pacific Pharma Sector Analysis
Antipsychotics Market Forecast
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes
Notable News in the Life Sciences: 3Q09